Sarepta Breaking News

Sarepta Therapeutics announces that their drug; Eteplirsen has shown some amazing results.

Participants in the trial have been shown to be producing dystrophin and achieving clinically significant benefits as measured by the 6-Minute Walk Test, this is after 48 Weeks of Treatment.

The results are from the Phase IIb Study in Duchenne Muscular Dystrophy.

Oct 03, 2012 Sarepta Therapeutic, announced that treatment with its lead exon-skipping compound, eteplirsen, met its primary efficacy endpoint. This means that it an increase in novel dystrophin has been shown and participants in the trial achieved a significant clinical benefit on the primary clinical outcome, measured by the 6-minute walk test (6MWT) compared with the placebo/delayed treatment cohort . 

Eteplirsen administered once weekly at either 30 mg/kg or 50 mg/kg for 48 weeks (n=8) resulted in a statistically significant increase (p≤0.001) in dystrophin-positive fibers to 47.0% of normal. 

The placebo/delayed treatment cohort, which had received 24 weeks of eteplirsen at either 30 mg/kg or 50 mg/kg following 24 weeks of placebo (n=4), also showed a statistically significant increase in dystrophin-positive fibers to 38.3% of normal (p≤0.009).

"These data represent a significant milestone and a defining moment of progress and hope for patients with DMD and their families, as well as for those of us in the scientific community who have been pursuing potential treatments for this devastating and deadly disease for decades," said Jerry Mendell, M.D., Director of the Centers for Gene Therapy and Muscular Dystrophy at Nationwide Children's Hospital and principal investigator of the Phase IIb study. 

Dr. Mendell added, "By addressing the underlying cause of DMD, eteplirsen has demonstrated unparalleled effects on enabling dystrophin production and slowing the progression of the disease as measured by the 6-minute walk test, with no treatment associated adverse events. 

While eteplirsen is targeted to DMD patients with a specific genetic mutation, I think the implications for all DMD patients with related genetic mutations are clearly evident."

Click here to

< Return to DMD News